'Frequent Flyer' With a Vaso-Occlusive Crisis: Advocacy, Stigma, and the Individualized Analgesic Plan
Mr. J is 34 with sickle cell disease (HbSS) on hydroxyurea. He has had 8 emergency visits and 3 admissions in 6 months. Tonight he arrives at 22:00 with 10/10 back and leg pain, no fever, SpO2 97% on room air. He asks for 'Dilaudid 2 mg IV - that's the only thing that works' and says his last home dose was 6 hours ago. The triage note reads 'frequent flyer, likely drug-seeking.' The PDMP shows no overlapping prescriptions and no early refills. His home regimen is extended-release morphine 30 mg twice daily plus immediate-release morphine 15 mg every 4 hours as needed. A urine drug screen from a prior visit last month was negative for opioids. The night resident says, 'Let's give saline and see if he's faking.'
1. What are your assessment priorities in the first 30 minutes, and how do you interpret the negative urine drug screen and the specific drug request?
Read the worked answer
Assess for the things that kill people with sickle cell disease before you assess credibility.
- Vital signs including temperature and SpO2, work of breathing, chest pain, and auscultation - acute chest syndrome is the leading cause of death and can present with pain out of proportion to exam findings.
- Neurologic exam for stroke, abdominal exam for hepatic or splenic sequestration, and ask about priapism.
- Hydration status and ability to take oral fluids; site and character of pain compared with his usual crisis; any new focal findings.
- Ask what has worked before and what dose relieved him - his history is data, not manipulation.
The negative urine drug screen
- It does not prove diversion or non-use. Morphine is rapidly metabolized; a dilute specimen, a specimen collected many hours after a dose, or a lab assay with a high cutoff can all yield a negative result. It also cannot tell you whether he takes his medication as prescribed between crises.
- It also cannot be used to justify withholding analgesia in a patient with a confirmed, painful, life-shortening disease.
The specific drug request
- Naming the drug and dose that has worked before is common in sickle cell disease and reflects years of experience, not necessarily addiction. The relevant question is not 'why that drug' but 'what is his total daily opioid exposure and how do we dose above tolerance safely?'
- His home regimen is roughly 150 mg oral morphine equivalents per day - he is opioid-tolerant, and a standard 1 mg hydromorphone dose will be inadequate and will read as drug-seeking behavior when it fails.
Treat the pain now; investigate in parallel, not instead.
2. The resident proposes giving saline as a test. How do you respond, and what do you propose instead?
Read the worked answer
Name the problem clearly and professionally.
- Saline as a 'test' is deception. It removes his ability to consent to what is being done to him, and it is not a validated diagnostic test for anything. A patient who reports relief from saline is not thereby proven to be malingering - placebo response occurs in genuine pain.
- It causes harm: hours of untreated severe pain, worsened central sensitization, and a documented reason for him to avoid the hospital in the future, which is how patients die at home of acute chest syndrome.
- Withholding analgesia based on a triage label is a patient-safety event, not a cautious choice. 'Frequent flyer' is a judgment about a person, not a clinical finding, and it should never be the reason a plan is written.
Instead, offer a plan the team can defend
- Treat now with a tolerance-adjusted opioid: a hydromorphone PCA with demand dose around 0.4-0.6 mg, 6-8 minute lockout, and a small or no basal, plus reassessment at 30 minutes and a documented sedation score. Consider intranasal fentanyl for rapid onset while access is obtained.
- Multimodal adjuvants: scheduled acetaminophen, a ketamine infusion or sub-dissociative boluses for refractory vaso-occlusive pain, NSAIDs only if renal function is acceptable, and incentive spirometry hourly while awake - the last is a mortality intervention, not a comfort measure.
- Escalate the conversation, not the conflict: ask the resident to explain on what clinical grounds the dose would change if the pain were believed; if the answer is 'none,' the objection is about trust, not pharmacology. Involve the attending, the hematology service, and the charge nurse.
- Document objectively in the record: pain scores, sedation scores, exam findings, and the plan - not characterizations of the patient.
3. Build the individualized pain plan that should follow him out the door, and identify what the unit should change at the system level.
Read the worked answer
Individualized acute-plan elements
- A written, patient-specific regimen agreed on with hematology and the patient: baseline opioid requirement in oral morphine equivalents, preferred agent and dose for crises, adjuvants, and what has failed before.
- A tolerance-adjusted PCA rather than intermittent boluses; anticipatory prescribing so the 03:00 reassessment does not become a negotiation.
- Screen every visit for acute chest syndrome, stroke, sequestration, and priapism; document SpO2 and incentive spirometry use.
- Address hydroxyurea adherence and access to the sickle cell specialist; referral to a hematology day-unit or infusion center as an alternative to the ED for uncomplicated crises.
- Behavioral health and social work involvement offered, not imposed - and not made a precondition for analgesia.
- Discharge with a follow-up appointment made before he leaves and a documented plan for what to do if pain escalates.
System-level changes
- Remove 'frequent flyer' and 'drug-seeking' from the vocabulary of triage; audit charts for stigmatizing language.
- Create a sickle cell care pathway with a standard order set, an individualized plan filed in the EHR, and rapid triage to a bed for known vaso-occlusive crisis.
- Educate staff on opioid tolerance math and on the fact that requesting a specific opioid is a normal consequence of lived experience with a painful disease.
- Track a process metric (time from arrival to first analgesic) and a safety metric (rates of acute chest syndrome, ICU transfer) rather than visits per patient, which measures stigma rather than care.
Advocacy is the nursing intervention here: your documentation and your escalation tonight determine whether the next nurse inherits a label or a plan.